Worried about prostate cancer but unsure what your PSA test results really mean?

The Prostate Health Index (PHI) is a blood test that gives a clearer picture of your prostate cancer risk. Unlike the standard prostate-specific antigen (PSA) test, which can’t always tell the difference between benign prostatic hyperplasia and significant prostate cancer, the PHI combines three biomarkers to improve accuracy. Studies suggest PHI may improve the detection of aggressive prostate cancer early, help reduce unnecessary biopsies, and inform better screening decisions.

This article explains what the Prostate Health Index is, how it works, and why it matters for detecting prostate cancer.

The Prostate Health Index (PHI) is a blood test that helps doctors evaluate a man's risk for prostate cancer more accurately than the traditional prostate-specific antigen test. It combines three biomarkers—total PSA, free PSA, and [-2] pro PSA (proenzyme prostate-specific antigen)—into a single score to support more effective risk stratification during prostate cancer screening.

Unlike the standard PSA test, which can’t always distinguish between prostate cancer and benign prostatic hyperplasia, the PHI may help differentiate prostate cancer from benign disease. Studies support its use in men with elevated PSA but normal digital rectal exam findings, where cancer risk is unclear. This makes PHI a potentially valuable tool in identifying clinically significant prostate cancer and reducing unnecessary biopsies, according to studies cited in Cancer Epidemiol Biomarkers Prev and Clin Chem Lab Med.

The PHI score is calculated using a formula that includes three types of prostate-specific markers, all measured from a blood sample. These markers help doctors estimate the likelihood of prostate cancer, even in cases where the digital rectal examination findings are inconclusive or when the prostate-specific antigen test falls within the borderline range of 2–10 ng/mL.

Total PSA reflects the overall level of prostate-specific antigen in the blood. While levels above 2 ng/mL can raise suspicion, they are not specific to cancer and may also result from benign prostatic conditions or increased prostate volume. That’s why additional metrics like PHI and PSA density are considered in clinical evaluations.

Free PSA is the unbound form of prostate-specific antigen. A low percent free PSA is often linked to a higher chance of aggressive prostate cancer, making it a critical factor in the PHI formula. It is often used alongside complex prostate-specific antigens to improve test specificity.

[-2] pro PSA (proenzyme prostate-specific antigen) is a subtype of proenzyme prostate-specific antigen that is more closely associated with high-grade prostate cancer. Including this marker improves the PHI’s ability to identify significant prostate cancer. Studies in Cancer Epidemiol Biomarkers Prev have supported its role in early detection strategies.

The formula used to calculate the PHI is:

([-2]pro PSA / free PSA) × √total PSA

This equation produces a PHI score that offers better insight into the probability of prostate cancer than total and free PSA alone, helping guide decisions on further testing or surveillance.

The PHI score falls into different ranges that help guide decisions about further testing, like a prostate biopsy. These ranges indicate the likelihood of detecting prostate cancer or significant disease on biopsy.

A PHI score below 25 suggests a low risk of prostate cancer. Men in this group may avoid unnecessary biopsies and instead focus on regular prostate health monitoring. This helps lower anxiety and prevent overtreatment of benign disease.

A score between 25 and 35 may indicate an uncertain risk. Doctors might recommend repeat testing, magnetic resonance imaging (MRI), or closer follow-up. This range may raise concern for prostate cancer and lead doctors to consider a biopsy or additional diagnostic tests as part of careful biopsy decision management to support early detection.

Scores above 35 point to a higher chance of aggressive prostate cancer or clinically significant prostate cancer. In this case, further tests like a digital rectal examination, transrectal ultrasound, or initially extended prostate biopsies may be necessary to confirm a prostate cancer diagnosis.

The PHI test adds value to clinical practice by improving prostate cancer detection and helping avoid unnecessary procedures. It’s especially useful in distinguishing prostate cancer from benign prostatic hyperplasia, which often raises PSA levels but doesn’t require treatment.

Compared to the PSA test alone, some research suggests PHI offers improved risk stratification for men with elevated serum PSA between 2-10.0 ng/mL. This may result in fewer false positives, better targeting of prostate cancer screening, and fewer missed cases of high-grade cancer.

Men with a total PSA level between 2 and 10 ng/mL are ideal candidates for PHI testing. This group often faces unclear results from PSA screening alone. The PHI can improve biopsy decision management in these cases.

Men with a family history of prostate cancer or those with clinical risk factors identified by the American Cancer Society or National Comprehensive Cancer Network should also consider PHI testing. It may fit into routine prostate cancer screening and help improve the prediction of cancer risk.

Getting ready for a Prostate Health Index test is easy, but a few simple steps can help make sure your results are accurate. Your doctor may provide specific instructions based on your health history or recent exams.

Here’s what to keep in mind before your PHI test:

• You usually do not need to fast before the test.

• Avoid ejaculation for 24–48 hours, as it may affect PSA levels.

• Tell your doctor about any medications or supplements you’re taking.

• Wait a few days after a digital rectal examination or transrectal ultrasound if recently done.

• Follow your doctor’s timing if you’ve had a prostate biopsy or other prostate-related procedures.

The PHI test itself is a routine blood draw, completed quickly at most clinics or labs.

Once you receive your Prostate Health Index score, your next steps will depend on your risk level. Your doctor will use your PHI score, along with other clinical risk factors, to decide the best approach.

Here’s what your score could mean:

• Low PHI score (below 25): Low risk of prostate cancer; your doctor may recommend regular PSA screening and routine monitoring.

• Intermediate PHI score (25–35): Possible risk of clinically significant prostate cancer; further tests like imaging or repeat PSA may be advised.

• High PHI score (above 35): Higher probability of prostate cancer, especially aggressive prostate cancer; a prostate biopsy or additional diagnostic tests may be recommended.

These steps can help doctors personalize care, potentially reduce unnecessary biopsies, and support better prostate cancer detection and management.

The Prostate Health Index test is widely available, especially in facilities that specialize in prostate cancer detection and diagnosis. If you're at higher risk or have elevated PSA levels, your doctor can guide you on where to get tested.

Here are common places to access the PHI test:

• Urologist offices: Most urologists offer PHI testing as part of prostate cancer screening and risk evaluation.

• Specialized diagnostic labs: Some labs focus on men’s health and may provide PHI testing directly with a referral.

• Hospitals and cancer centers: Facilities with oncology or urology departments often offer the test along with other cancer screening tools.

• Primary care clinics: Some primary care providers can refer you for PHI testing if your PSA levels are elevated.

Always check if a referral is required and confirm coverage with your insurance provider before scheduling the test.

Click here to learn more about Alerna's Prostate Support Supplements to enhance your prostate health and overall well-being!

The Prostate Health Index (PHI) plays a key role in improving prostate cancer detection, especially for men with PSA levels between 2 and 10 ng/mL. Unlike the PSA test alone, the PHI helps doctors better distinguish prostate cancer from benign conditions like benign prostatic hyperplasia.

This added accuracy lowers the chances of unnecessary biopsies and supports earlier diagnosis of aggressive prostate cancer. If you have concerns about your prostate health or elevated PSA levels, talk to your doctor to find out if PHI testing is right for you. Taking this step can improve your chances of timely treatment and better outcomes.

The information provided in this article is for educational and informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Please consult with your healthcare provider before starting any new dietary supplement, especially if you are pregnant, nursing, have a medical condition, or are taking other medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

1. Agnello, L., Vidali, M., Giglio, R. V., Gambino, C. M., Ciaccio, A. M., Lo Sasso, B., & Ciaccio, M. (2022). Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clinical chemistry and laboratory medicine, 60(8), 1261–1277. https://doi.org/10.1515/cclm-2022-0354

2. Lojanapiwat, B., Anutrakulchai, W., Chongruksut, W., & Udomphot, C. (2014). Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate international, 2(3), 133–139. https://doi.org/10.12954/PI.14054